Search Results
Belinostat
Belinostat is FDA approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
High School Student Proves Youngest Generation Can Make an Impact on Cancer Research and Cures
Ella Behnke of San Antonio, Texas, is a 16-year-old cheerleader who attends Alamo Heights High School and is making history, as the winner of The Leukemia & Lymphoma Society’s (LLS) national title “Student of the Year.” Ella raised more than $334,768 for LLS to invest in cancer cures with an intense seven-week fundraising campaign involving everything from a very active campaign team, social media activations to visiting cancer patients at the Children’s Hospital of San Antonio.
#ASH15 Day 4: Breakthrough Therapy Designation for Novel Immunotherapy
Yesterday we learned the exciting news that the FDA has granted Breakthrough Therapy designation for an investigational immunotherapy LLS is supporting through our Therapy Acceleration Program (TAP).
3 Insights from a Clinical Trial Patient
The road to finding new and better cancer treatments often includes an important step: clinical trials. For patients with hard-to-treat diseases, these studies can be superhighways to the right treatment. A clinical trial can tell oncologists whether a new treatment works, how certain cancer types affect the body, and more.
A phase 1/2 study of DR-01, an anti-CD94 monoclonal antibody, in patients with large granular lymphocytic leukemia or cytotoxic lymphomas
In November 2022, LLS made an equity investment in Dren Bio to "Support Clinical Development of the DR-01 Program for Rare Leukemia & Lymphoma Indications Including Large Granular Lymphocyte Leukemia (LGLL) and Cytotoxic Lymphomas."
Champions in myeloma research: A conversation with Urvi A. Shah, M.D. M.S.
March is Myeloma Awareness Month, and it’s also Women’s History Month. So what better time to spotlight LLS-funded women scientists who are driving discovery for myeloma patients.
In this first of my two-part series on myeloma researchers, I sat down with Urvi A. Shah, MD, MS, an Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center.
Mechlorethamine
Mechlorethamine is FDA approved to treat people who have Hodgkin lymphoma, chronic myeloid leukemia, chronic lymphocytic leukemia, polycythemia vera and mycosis fungoides.
Vinblastine
Vinblastine is an FDA-approved chemotherapy agent that is used to treat people who have acute leukemia. It is sometimes used to treat other types of cancer including lymphoma.
Vorinostat
Vorinostat is FDA approved to treat cutaneous T-cell lymphoma (CTCL) in patients whose CTCL gets worse, does not go away or comes back after treatment with two systemic therapies.
Bendamustine hydrochloride
Bendamustine hydrochloride is FDA approved to treat people who have:
- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Denileukin diftitox-cxdl
Denileukin diftitox-cxdl is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.